Prostate cancer survival is dependent on season of diagnosis

Prostate

Volumn 67, Issue 12, 2007, Pages 1362-1370

  Lagunova, Zoya ^a   Porojnicu, Alina Carmen ^a   Dahlback, Arne ^b   Berg, Jens Petter ^c   Beer, Tomasz M ^d   Moan, Johan ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Latitude dependency; Prognosis; Prostate cancer; Seasonal variation; Vitamin D

Indexed keywords

CALCITRIOL; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SEASONAL VARIATION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

AGED; ANIMALS; CALCIFEDIOL; CARCINOMA, SQUAMOUS CELL; DIET; FISHES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; SEASONS; SUNLIGHT; SURVIVAL ANALYSIS;

EID: 34548763826     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20577     Document Type: Article

References (67)

1. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20:680-688.
2. World Health Organisation Statistical Information System. WHO Mortality database. 2006.
3. Moon SJ, Fryer AA, Strange RC. Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseases. Photochem Photobiol 2005;81:1252-1260.
4. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307-1311.
5. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-108.
6. Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006;24:184-194.
7. Beer TM. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005;96:508-513.
8. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005;65:5470-5479.
9. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC. Susceptibility to prostate cancer: Studies on interactions between UVR exposure and skin type. Carcinogenesis 2003;24:711-717.
10. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Associations between prostate cancer susceptibility and parameters of exposure to ultraviolet radiation. Cancer Lett 2003;200:141-148.
11. Freedman DM, Dosemeci M, McGlynn K. 1 Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: A composite death certificate based case-control study. Occup Environ Med 2002;59:257-262.
12. John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89-90:549-552.
13. Schwartz GG, Hanchette CLUV. latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-1101.
14. Bodiwala D, Luscombe CJ, Liu S, Saxby M, French M, Jones PW, Fryer AA, Strange RC. Prostate cancer risk and exposure to ultraviolet radiation: Further support for the protective effect of sunlight. Cancer Lett 2003;192:145-149.
15. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW, Strange RC. Exposure to ultraviolet radiation: Association with susceptibility and age at presentation with prostate cancer. Lancet 2001;358:641-642.
16. Weinrich S, Ellison G, Weinrich M, Ross KS, Reis-Starr C. Low sun exposure and elevated serum prostate specific antigen in African American and Caucasian men. Am J Health Stud 2001; 17:148-155.
17. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89-90:533-537.
18. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-432.
19. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15: 255-265.
20. Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004;15:149-158.
21. Moan J, Porojnicu AC, Robsahm TE, Dahlback A, Juzeniene A, Tretli S, Grant W. Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B 2005;78:189-193.
22. Porojnicu AC, Robsahm TE, Hansen Ree A, Moan J. Season of diagnosis is a prognostic factor in Hodgkin lymphoma. A possible role of sun-induced vitamin D. Br J Cancer 2005;93:571-574.
23. Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani DC, Moan J. Seasonal and geographical variations in lung cancer prognosis in Norway. A possible beneficial role of sun-induced vitamin D. Lung Cancer 2007;55:263-270.
24. Porojnicu AC, Lagunova Z, Berg JP, Dahlback A, Moan J. Changes in risk of death from breast cancer with season and latitude. Breast Cancer Res Treat 2007;102:323-328.
25. Moan J, Porojnicu AC. The photobiology of vitamin D-a topic of renewed focus. Tidsskr Nor Laegeforen 2006;126:1048-1052.
26. Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 2006;119:1530-1536.
27. Boniol M, Armstrong BK, Dore JF. Variation in incidence and fatality of melanoma by season of diagnosis in new South Wales, Australia. Cancer Epidemiol Biomarkers Prev 2006;15:524-526.
28. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:2303-2309.
29. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-459.
30. Holick MF. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79:362-371.
31. Need AG, Morris HA, Horowitz M, Nordin C. Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr 1993;58:882-885.
32. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985;76:1536-1538.
33. Falch JA, Oftebro H, Haug E. Early postmenopausal bone loss is not associated with a decrease in circulating levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, or vitamin D-binding protein. J Clin Endocrinol Metab 1987;64:836-841.
34. Johansson L, Solvoll K, Norkost, 1997 Norwegian National Dietary Survey, Oslo: Statens råd for ernæring of fysisk aktivitet. 1999.
35. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks GC, Gaffney P, Battistutta D, Frost C, Lang C, Russell A. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet 1999;354:723-729.
36. Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer 2007;120:1123-1128.
37. Statistics Norway 2006.
38. Holick MF. Vitamin D: A millenium perspective. J Cell Biochem 2003;88:296-307.
39. Lai H. Vitamin D: Non-skeletal actions and effects on growth. Nutrition Res 1999;19:1683-1718.
40. Adams JS, Clemens TL, Parrish JA, Holick MF. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 1982;306:722-725.
41. Moan J, Dahlback A, Henriksen T, Magnus K. Biological amplification factor for sunlight-induced nonmelanoma skin cancer at high latitudes. Cancer Res 1989;49:5207-5212.
42. Moan J, Dahlback A. The relationship between skin cancers, solar radiation and ozone depletion. Br J Cancer 1992;65:916-921.
43. Moan J, Dahlback A. Ultraviolet radiation and skin cancer: Epidemiologic data from Scandinavia. In: Bjorn LO, Moan J, Nultsch W, Young AR, editors. Environmental UV Photobiology. New York: Plenum Press; 1993, pp 192-255.
44. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet 1989;2:1104-1105.
45. Brustad M, Sandanger T, Aksnes L, Lund E. Vitamin D status in a rural population of northern Norway with high fish liver consumption. Public Health Nutr 2004;7:783-789.
46. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: Critical need for revision upwards. J Nutr 2006;136:1117-1122.
47. Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-1101.
48. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005;165:1005-1010.
49. Velicer CM, Kristal A, White E. Alcohol use and the risk of prostate cancer: Results from the VITAL cohort study. Nutr Cancer 2006;56:50-56.
50. Grant WB. A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality. Eur Urol 2004; 45:271-279.
51. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin d receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15:2239-2245.
52. Beer TM, Myrthue A. Calcitriol in cancer treatment: From the lab to the clinic. Mol Cancer Ther 2004;3:373-381.
53. Bonaccorsi L, Marchiani S, Ferruzzi P, Muratori M, Crescioli C, Forti G, Maggi M, Baldi E. Non-genomic effects of the androgen receptor and Vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids 2006;71: 304-309.
54. Marchiani S, Bonaccorsi L, Ferruzzi P, Crescioli C, Muratori M, Adorini L, Forti G, Maggi M, Baldi E. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 2006;132:408-416.
55. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888-894.
56. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005;97:31-36.
57. Zhao XY, Feldman D. The role of vitamin D in prostate cancer. Steroids 2001;66:293-300.
58. Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000;164:133-143.
59. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003;164:205-221.
60. Polek TC, Weigel NL. Vitamin D and prostate cancer. J Androl 2002;23:9-17.
61. Bao BY, Yao J, Lee YF. 1Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006;27:1883-1893.
62. Bao BY, Yeh SD, Lee YF. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006;27:32-42.
63. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
64. Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol 2005;23:28-32.
65. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007;59:581-587.
66. Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D compounds: Clinical development as cancer therapy and prevention agents. Anticancer Res 2006;26:2551-2556.
67. Grant WB, Garland CF. A critical review of studies on vitamin D in relation to colorectal cancer. Nutr Cancer 2004; 48:115-123.